$GH

Monroe Terilyn J. sold $7.6M of GH

Monroe Terilyn J. (Chief People Officer) sold 46,300 shares of Guardant Health, Inc. (GH) at an average of $165.12 ($163.41–$167.92, $7.65M total) across 5 trades on 2026-08-12.

Original reporting
SEC EDGAR · Monroe Terilyn J.
Published Aug 13, 2026, 11:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 11:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The newest disclosed fact is the open-market sale of 46,300 shares across five trades at an average price of about $165.12, totaling about $7.65M, with holdings after the sale of 22,979 shares.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone does not change Guardant’s fundamentals.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-scheduled personal liquidity needs; without additional context, the signal is weak.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-13, trades executed 2026-08-12

Background

This is an SEC Form 4 insider transaction for Guardant Health, Inc. (GH) by Chief People Officer Monroe Terilyn J.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Guardant Health insider Monroe Terilyn J. sold about $7.65M of GH shares in open-market trades on 2026-08-12.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than fundamentals.

Evidence & confidence

Form 4 insider sales are common and often non-informational; the article provides transaction size and timing but no accompanying company news or guidance change.

Market effects

Minimal, as this is company-specific insider trading with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

The absence of a disclosed 10b5-1 plan could be interpreted by some traders as higher signaling risk, potentially increasing short-term sensitivity to further insider activity.

Key entities

  • Guardant Health, Inc.

    Company whose shares were sold by an insider in the reported Form 4.

  • Monroe Terilyn J.

    Chief People Officer who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHMed

Guardant Health (GH) Surges on FDA Approval and Cancer Screening Momentum

Aristotle Capital Management’s Core Equity Fund Q2 2026 letter said its fund gained 14.69% in Q2 2026. It highlighted Guardant Health (GH), citing FDA approval of an updated Guardant360 liquid biopsy test, American Cancer Society inclusion of its Shield colorectal screening test, and stronger-than-expected Q1 earnings. GH closed Aug. 14, 2026 near $157.21.

$GHHighAI 9/10

Guardant Health (GH) Q2 2026 Earnings Call Transcript

Guardant Health (GH) reported Q2 2026 revenue of $335 million, up 44% year over year, driven by Oncology, Biopharma & Data, and Screening. Oncology revenue was $219.1 million, up 38%, with test volumes around 104,000. Full-year guidance: revenue $1.34 to $1.36 billion and free cash flow burn $195 to $205 million.